Powered 500 · 2026POWEREDS. 422 of 500
Mainolfi founded Kymera Therapeutics and raised over $1 billion to advance oral small molecule degraders — a class of medicines capable of hitting disease targets that conventional drugs cannot reach — pushing multiple first-in-class programs into clinical development.
Nello Mainolfi founded Kymera Therapeutics, a clinical-stage biotech advancing oral small-molecule degraders against disease targets inaccessible with conventional therapeutics.
Kymera has progressed multiple first-in-class programs into clinical trials, raised over $1 billion, and partnered with major biopharmaceutical companies. Before Kymera, Mainolfi was an entrepreneur in residence at Atlas Venture and led drug discovery teams at Novartis.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
